2930-05-4 Usage
Description
BENZYL GLYCIDYL ETHER, also known as [(Phenylmethoxy)methyl]oxirane, is a glycidol derivative with significant potential in various applications due to its unique chemical properties. It is involved in the synthesis of atactic and isotactic linear poly(benzyl 1,2-glycerol carbonate)s and has been studied for its biocatalytic resolution by Talaromyces flavus and Bacillus alcalophilus cells. Additionally, it has been shown to have in vivo skin sensitizing potency and can induce Nrf2-Dependent Luciferase Activity in the KeratinoSens.
Uses
Used in Pharmaceutical Industry:
BENZYL GLYCIDYL ETHER is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its ability to induce Nrf2-Dependent Luciferase Activity in the KeratinoSens makes it a promising candidate for the development of new drugs targeting skin-related conditions.
Used in Polymer Synthesis:
BENZYL GLYCIDYL ETHER is used as a monomer in the production of atactic and isotactic linear poly(benzyl 1,2-glycerol carbonate)s. These polymers have potential applications in various industries, including the medical field, where they can be used for the development of biodegradable materials and drug delivery systems.
Used in Biocatalysis:
BENZYL GLYCIDYL ETHER is used as a substrate in biocatalytic resolution processes, such as those involving Talaromyces flavus and Bacillus alcalophilus cells. This application allows for the production of enantiomerically pure compounds, which are essential in the pharmaceutical industry for the development of more effective and selective drugs.
Used in Chemical Research:
BENZYL GLYCIDYL ETHER is used as a research compound for studying its chemical properties and potential applications in various fields. Its ability to react with K-, K+(15-crown-5)2 to afford potassium glycidoxide and bibenzyl makes it an interesting subject for further investigation and potential development of new chemical processes and products.
Check Digit Verification of cas no
The CAS Registry Mumber 2930-05-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,9,3 and 0 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2930-05:
(6*2)+(5*9)+(4*3)+(3*0)+(2*0)+(1*5)=74
74 % 10 = 4
So 2930-05-4 is a valid CAS Registry Number.
InChI:InChI=1S/C10H12O2/c1-2-4-9(5-3-1)6-11-7-10-8-12-10/h1-5,10H,6-8H2
2930-05-4Relevant articles and documents
Synthesis of N-lost derivatives, II: Reaction of n,n-bis(2-chloroethyl)phosphoramide dichloride with 1-aminopropane-2,3-diol
Lorenz,Wiessler
, p. 1023 - 1027 (1986)
-
Diastereoselective Alkene Hydroesterification Enabling the Synthesis of Chiral Fused Bicyclic Lactones
Shi, Zhanglin,Shen, Chaoren,Dong, Kaiwu
supporting information, p. 18039 - 18042 (2021/11/16)
Palladium-catalysed diastereoselective hydroesterification of alkenes assisted by the coordinative hydroxyl group in the substrate afforded a variety of chiral γ-butyrolactones bearing two stereocenters. Employing the carbonylation-lactonization products as the key intermediates, the route from the alkenes with single chiral center to chiral THF-fused bicyclic γ-lactones containing three stereocenters was developed.
A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration
González-Gil, Inés,Zian, Debora,Vázquez-Villa, Henar,Hernández-Torres, Gloria,Martínez, R. Fernando,Khiar-Fernández, Nora,Rivera, Richard,Kihara, Yasuyuki,Devesa, Isabel,Mathivanan, Sakthikumar,Del Valle, Cristina Rosell,Zambrana-Infantes, Emma,Puigdomenech, María,Cincilla, Giovanni,Sanchez-Martinez, Melchor,Rodríguez De Fonseca, Fernando,Ferrer-Montiel, Antonio V.,Chun, Jerold,López-Vales, Rubén,López-Rodríguez, María L.,Ortega-Gutiérrez, Silvia
supporting information, p. 2372 - 2390 (2020/01/02)
Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA1) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA1 agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA1 receptor agonist described so far (Emax = 118%, EC50 = 0.24 μM, KD = 19.6 nM; inactive at autotaxin and LPA2-6 receptors). This compound induces characteristic LPA1-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.
